Given the COVID-19 pandemic and the impossibility to meet in person, OTS will award two Lifetime Achievement Awards in 2021, to Dr. Ryszard Kole and Dr. Frank Bennett. Both will give their award lecture at the 2021 meeting. The Award Committee feels it is fitting to have these individuals as a ‘double bill’. Not only have both made important contributions to basic science, both were also instrumental in the development of antisense oligonucleotide drugs that modulate splicing to correct severe genetic disease. We look forward to the 2021 OTS meeting as a celebration of Dr. Kole and Dr. Bennett.
Paper of the Year Winners
July 2019 – June 2020
Congratulations to the Winner of the OTS Paper of the Year Award!
The Paper of the Year Award is designed to honor the most impactful papers in the field of oligonucleotide therapeutics.
In 2020, the OTS introduced two categories for Paper of the Year award, the Basic Research and Late Discovery categories. This change reflects the scope of excellent research being done in the field of oligonucleotide therapeutics.
Below are the details for each award.
Basic Paper Of The Year Award – Winners
This year, OTS has awarded three winners in the Paper of the Year – Basic Science category. They reveal that, contrary to expectations, gapmer antisense oligonucleotides that target noncoding transcripts can affect transcription. This conclusion affects how ASOs are used as tools to study noncoding RNAs and suggests a more complex relationship between noncoding RNAs and gene transcription.
For more detailed information on these three papers, click here.
- Directed RNase H cleavage of nascent transcripts causes transcription termination
Lai F, Damle SS, Ling KK, Rigo F.
- Antisense-mediated transcript knockdown triggers premature transcription termination
Dr. Joshua Mendell, Dr. Jong-Sun Lee
- A unified allosteric/torpedo mechanism for transcriptional termination on human protein-coding genes
Eaton JD, Francis L, Davidson L, West S.
Late Discovery Paper Of The Year Award – Winners
This year, OTS has awarded two winners in the Paper of the Year – Late Discovery category. In both cases the research examined the effect of inclisiran, which is a small interfering RNA, on LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia (Raal et al., 2020), or atherosclerotic cardiovascular disease (Ray et al., 2020), and reported significant reductions in levels of patients compared to controls.
To read more about these two papers, click here.
- Inclisiran for the treatment of heterozygous familial hyper-cholesterolemia
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators.
- Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators.